EW
Edwards Lifesciences Corp
Edwards Lifesciences Corp historical holders
total: 7
Fundsmith Edwards Lifesciences Corp transactions over time
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2022 Q3
- Held for:
- 3 quarters
- Latest activity:
- 2023 Q2
Terry Smith has been an institutional investor in Edwards Lifesciences Corp (EW) since 2022 Q3. According to 2026 Q1 report, Terry Smith doesn't hold any shares. The fund/company first acquired EW in 2022 Q3, initially purchasing 9,979 shares. Since the initial investment, Fundsmith has made 1 more transaction in this position.
When did Terry Smith exit their EW position?
Terry Smith no longer holds Edwards Lifesciences Corp (EW). They sold off their entire position in 2023 Q2, closing out an investment that began in 2022 Q3.
When did Terry Smith first invest in EW?
Terry Smith first invested in Edwards Lifesciences Corp (EW) in 2022 Q3 at the reported quarter-end price of $82.67 per share, acquiring 9,979 shares in their initial purchase.
What is Terry Smith's average cost basis for EW?
Based on historical transaction data, Terry Smith's estimated cost basis for Edwards Lifesciences Corp (EW) is approximately $82.67 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $82.67
- Weighted AVG sell price:
- $82.73
EW transactions history by Fundsmith
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q2
|
0.00%
|
0
|
$82.73
|
|
-100% (-9,979)
|
-0%
|
|
2022 Q3
|
0.00%
|
9,979
|
$82.67
|
$825,000
|
new
|
+0%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.